Efficacy and safety of rituximab in type II mixed cryoglobulinemia

Blood

Volumn 101, Issue 10, 2003, Pages 3827-3834

  Zaja, Francesco ^b   De Vita, Salvatore ^a   Mazzaro, Cesare ^b   Sacco, Stefania ^b   Damiani, Daniela ^b   De Marchi, Ginevra ^b   Michelutti, Angela ^b   Baccarani, Michele ^b   Fanin, Renato ^b   Ferraccioli, Gianfranco ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEPATITIS C; HUMAN; LABORATORY TEST; MALE; NEPHRITIS; PANNICULITIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; REMISSION; RENAL ARTERY THROMBOSIS; SKIN ULCER; TREATMENT OUTCOME; URTICARIA; VASCULITIS; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; REPRODUCIBILITY; SAFETY; TIME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037926826     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2856     Document Type: Article

References (33)

1. Dispenzieri A, Gorevic PD. Cryoglobulinaemia. Hematol Oncol Clin North America. 1999;13:1315-1349.
2. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia. Arthritis Rheum. 2000;43:94-102.
3. Misiani R, Bellavita P, Fenili D, et al. Interferon alpha 2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330:751-756.
4. Dammacco F, Sansonno D, Han JH, et al. Natural interferon alpha versus its combination with 6-metil-prednisolone in the therapy of type II mixed cryoglobulinemia: a long term, randomized, controlled study. Blood. 1994;84:3336-3343.
5. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood. 1997;90:3865-3873.
6. Coca P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2002;14:29-35.
7. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther. 1999;13:1179-1186.
8. Donada C, Crucitti A, Donadon W, Chemello L, Alberti A. Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia [letter]. Blood. 1998;92:2983-2984.
9. La Civita L, Zignego AL, Lombardini F, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol. 1996;22:1641-1643.
10. Cid MC, Hernandez-Rodriguez J, Robert J, et al. Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations. Arthritis Rheum. 1999;42:1051-1055.
11. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618-623.
12. Tavoni A, Mosca M, Ferri C, et al. Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol. 1995;13(suppl 13):S191-S195.
13. Ortmann RA, Klippel JH. Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26:363-375.
14. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
15. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-CD28 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
16. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29:105-112.
17. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 2002;46:1984-1985.
18. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia [letter]. Haematologica. 1999;84:1157-1158.
19. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli GF: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46:2029-2033.
20. Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia [letter]. Arthritis Rheum. 2002;46:2252-2254.
21. De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90:776-782.
22. Medical Research Council: aids to the examination of the peripheral nervous system. Memorandum no. 45. London, Her Majesty's Stationery Office, 1981.
23. Victor M, Ropper AH. Electrophysiologic testing and laboratory aids in the diagnosis of neuromuscular disease. In: Adams and Victor's Principles of Neurology. 7th ed. McGraw-Hill; 2001;1346-1369.
24. Takemura S, Klimiuk PA, Braun DA, Gorozny JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710-4718.
25. Chad D, Pariser K, Bradley WG, Adelman LS, Pinn VW. Pathogenesis of cryoglobulinemic neuropathy. Neurology. 1982;32:725-729.
26. Bonetti B, Scardoni M, Monaco S, Rizzuto N, Scarpa A. Hepatitis C virus infection of peripheral nerves in type II cryoglobulinemia. Virchows Arch. 1999;434:533-535.
27. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100:1765-1773.
28. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27(suppl 12):79-85.
29. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH51p1/VLkv325 immunoglobulin gene combination in hepatitis C virus associated immunocytomas. Blood. 1998;7:2433-2442.
30. De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96:3578-3584.
31. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001;98:3745-3749.
32. Carson D, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest. 1991;87:379-383.
33. De Vita S. Hepatitis C virus and mixed cryoglobulinemia: recent developments and perspectives for research [abstract]. Haematologica. 2002;87(suppl 1-9):11-12.